CCIA
PAHC icon

Campbell & Co Investment Adviser’s Phibro Animal Health PAHC Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PAHC Stock Details PAHC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$461K Sell
14,688
-12,918
-47% -$545K 0.02% 792
2026
Q1 		$1.53M Buy
27,606
+314
+1% +$14.9K 0.09% 358
2025
Q4 		$1.02M Buy
27,292
+7,825
+40% +$318K 0.05% 557
2025
Q3 		$788K Sell
19,467
-28,942
-60% -$956K 0.06% 524
2025
Q2 		$1.24M Buy
48,409
+5,987
+14% +$131K 0.08% 411
2025
Q1 		$906K Buy
42,422
+7,822
+23% +$175K 0.07% 471
2024
Q4 		$727K Buy
34,600
+665
+2% +$15.4K 0.06% 519
2024
Q3 		$764K Buy
33,935
+9,953
+42% +$192K 0.06% 541
2024
Q2 		$402K Buy
23,982
+7,941
+50% +$128K 0.03% 731
2024
Q1 		$207K Buy
16,041
+3,046
+23% +$36.5K 0.02% 1013
2023
Q4 		$150K Buy
+12,995
New +$147K 0.01% 1049
2023
Q2 		– Sell
-35,544
Closed -$545K – 1059
2023
Q1 		$545K Buy
35,544
+22,115
+165% +$338K 0.1% 388
2022
Q4 		$180K Sell
13,429
-9,748
-42% -$131K 0.04% 703
2022
Q3 		$308K Sell
23,177
-843
-4% -$14.6K 0.07% 469
2022
Q2 		$460K Sell
24,020
-5,226
-18% -$99K 0.12% 307
2022
Q1 		$583K Buy
29,246
+18,920
+183% +$382K 0.16% 217
2021
Q4 		$211K Buy
+10,326
New +$220K 0.07% 520
2021
Q3 		– Sell
-13,026
Closed -$376K – 723
2021
Q2 		$376K Buy
13,026
+3,433
+36% +$92.8K 0.15% 239
2021
Q1 		$234K Buy
+9,593
New +$217K 0.14% 309
2019
Q2 		– Sell
-10,667
Closed -$352K – 660
2019
Q1 		$352K Buy
10,667
+2,462
+30% +$76.6K 0.17% 223
2018
Q4 		$292K Buy
8,205
+1,225
+18% +$46.2K 0.29% 162
2018
Q3 		$299K Sell
6,980
-4,391
-39% -$207K 0.2% 221
2018
Q2 		$524K Buy
11,371
+1,700
+18% +$75.3K 0.4% 51
2018
Q1 		$384K Sell
9,671
-400
-4% -$14.8K 0.32% 102
2017
Q4 		$337K Sell
10,071
-3,223
-24% -$114K 0.25% 149
2017
Q3 		$493K Buy
13,294
+880
+7% +$33K 0.4% 62
2017
Q2 		$460K Buy
12,414
+4,286
+53% +$140K 0.43% 58
2017
Q1 		$228K Buy
+8,128
New +$229K 0.59% 87

Other funds holding PAHC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Campbell & Co Investment Adviser's PAHC Position: Q2 2026 in Review

Campbell & Co Investment Adviser reduced its Phibro Animal Health (PAHC) stake by 47% in Q2 2026, selling an estimated $545K and leaving 14,688 shares worth $461K. The position accounts for 0.02% of the portfolio, ranked #792.

Campbell & Co Investment Adviser first reported a position in PAHC in Q1 2017 and has held it in 28 quarters since. The position peaked at $1.53M in Q1 2026. 208 funds tracked by Wall St. Rank hold PAHC as of Q2 2026.

  • Campbell & Co Investment Adviser held 14,688 shares of Phibro Animal Health worth $461K as of Q2 2026.
  • Campbell & Co Investment Adviser sold 12,918 Phibro Animal Health shares in Q2 2026, an estimated $545K.
  • Phibro Animal Health made up 0.02% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #792 holding.
  • Campbell & Co Investment Adviser first reported a position in Phibro Animal Health in Q1 2017 and has held it in 28 quarters since.
  • Campbell & Co Investment Adviser's Phibro Animal Health position peaked at $1.53M in Q1 2026.
  • 208 funds tracked by Wall St. Rank held Phibro Animal Health as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.